https://unauthorised investment advice/experts/dr-borehams-crucible-is-this-a-case-of-whats-good-for-mesoblast-is-good-for-cynata/
The new leader at Cynata is telling the market that their P2 GVHD FDA trial (that hasn't started yet) might 'just possible' be soooooo good that the FDA will let them commercialize without a P3. P3's are optional - that's new - why has SI been wasting our time and money on them??!!
'It's possible - just possible'.....from a person that has never started a FDA trial (neither P1, P2 or P3), let alone finished one.
It's possible - just possible, that he and they are speaking fluent arse.
It a 'stranger than fiction' way, the new chief suits the shareholders.
2023 The Final Countdown, page-3015
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |